Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes-Reference-Cited by-同舟云学术

Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes

Published:2019-03-20 Issue:3 Volume:369 Page:428-442
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Pognan Francois,Couttet Philippe,Demin Ivan,Jaitner Birgit,Pang Yinuo,Roubenoff Ronenn,Sutter Esther,Timsit Yoav,Valentin Marie Anne,Vogel Beate,Woerly Gaetane,Wolf Armin,Schramm Ursula

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference42 articles.

1. Role of the colony-stimulating factor (CSF)/CSF-1 receptor axis in cancer

2. Macrophage depletion attenuates extracellular matrix deposition and ductular reaction in a mouse model of chronic cholangiopathies;Best;PLoS One,2016

3. Plasma clearance and endocytosis of cytosolic malate dehydrogenase in the rat

4. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis

5. Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors;Calvo;J Clin Oncol,2018

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Macrophage’s role in solid tumors: two edges of a sword;Cancer Cell International;2023-07-31

2. CSF1R as a Therapeutic Target in Bone Diseases: Obvious but Not so Simple;Current Osteoporosis Reports;2022-10-05

3. Liver enzyme delayed clearance in rat treated by CSF1 receptor specific antagonist Sotuletinib;Current Research in Toxicology;2022

4. Radiolabeled Monoclonal Antibody Against Colony-Stimulating Factor 1 Receptor Specifically Distributes to the Spleen and Liver in Immunocompetent Mice;Frontiers in Oncology;2021-12-16

5. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer;Clinical Cancer Research;2021-10-06